Navigation Links
ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
Date:6/24/2009

BLACK MOUNTAIN, N.C., June 24 /PRNewswire/ -- ALP Life Sciences, LLC (Company) today announced the Nanoveson(TM) patent has been filed and the Nanoveson(TM) whitepaper is available at www.ALPLifeSciences.com/wp. After completing initial research, the Company is pursuing clinical trials and FDA regulatory approval of Nanoveson(TM) as a prescription drug treatment for non-alcoholic fatty liver disease (NAFLD).

Over 60 million adult Americans suffer from NAFLD and these numbers are rising rapidly. There is no FDA approved NAFLD treatment. NAFLD is a global health crisis. NAFLD is also associated with the metabolic syndrome and other life threatening diseases. NAFLD is known to progress to more advanced liver diseases such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and liver cancer.

Nanoveson(TM) is a novel approach to treating and diagnosing liver diseases and comorbid diseases utilizing the principles of Applied Lipid Polymorphism, which includes a revolutionary application of nanobiotechnology in the area of self-organizing lipid membranes. Nanoveson(TM) therapy utilizes only natural compounds. The therapy triggers liver triglyceride remodeling into bile phospholipids and lipid membrane fusion and aggregation in the intestines. Molecular compounds including biliary phospholipids, arachidonic acid metabolites, cholesterol, methyl metabolites, phthalate esters, and other compounds sequestered in vesicle membranes are expected to be a rich source of disease state biomarkers. Nanoveson(TM) also has the potential to provide extensive support to the life sciences industry in the area of drug metabolism testing.

Research has demonstrated that enterohepatic circulation is the mechanism that maintains quantitative whole body homeostasis of arachidonic acid. There is extensive research focused on blocking arachidonic acid metabolism along cytochrome P450, leukotriene, prostaglandin, and thromboxane eicosanoid pathways. Arachidonic acid metabolism is implicated in many inflammatory diseases, including cardiovascular diseases, gastrointestinal diseases, arthritis, asthma, diabetes and cancer. Nanoveson(TM) therapy may improve enterohepatic circulation by removing excess triglyceride deposits in the liver and improving bile flow; having a positive therapeutic impact on arachidonic acid driven disease states by reducing arachidonic acid availability for inflammatory metabolism. Orphan disease indication targets for inflammatory diseases may be pursed through clinical trials focused on arachidonic acid specific surrogate end points.

David K. Barker, Founder and CEO of ALP Life Sciences, LLC stated, "The preliminary evidence for the Nanoveson(TM) hypotheses is very promising, however, it should be emphasized that the complex mechanisms of action triggered by Nanoveson(TM) must be quantified, and the efficacy for targeted indications must be established by clinical trials." Barker added, "I'd like to take this opportunity to acknowledge the many scientists and physicians referenced in the Nanoveson(TM) whitepaper. Without their dedication to medical research the preliminary research and hypotheses presented in the Nanoveson(TM) whitepaper would not have been possible. However, nothing in this release or in the whitepaper suggests referenced researchers endorse the preliminary conclusions presented at this time."

ALP Life Sciences, LLC is a life sciences research and development company focused on therapeutics and diagnostics based on the new and emerging science of Applied Lipid Polymorphism. ALP Life Sciences, LLC is currently evaluating strategic relationships in the area of principal investigators, clinical trial facilities, medical school research partnerships, manufacturing, commercialization, global licensing and partnering opportunities for therapy, diagnostics and drug metabolism testing. Relationships with medical research foundations, public institutes of health, and life sciences venture capital firms are also being evaluated. Interested parties should contact ALP Life Sciences, LLC.


'/>"/>
SOURCE ALP Life Sciences, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat
2. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
3. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
4. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
5. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a total ... & Co., Inc., Biogen and Sanofi are involved in the development of ... which one is in Phase III stage, 15 are in Phase II ...
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
(Date:3/24/2017)... surveys with 9,250 insured consumers fielded from February 2015 ... help from their plans in five key areas: 1) ... help closing gaps in care, 3) better digital connections, ... real-time guidance. Meeting these needs is essential to promoting ... A Reason to Stay Engaged in Health ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social Media: ... journal chronicling the writer’s path toward true communion with God. “Finding Christ Through ... is the creation of published author Lea Michelle Johnson, a follower of Christ, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... ... 2017 , ... A recent report from the National Council on Teacher Quality ... report suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions ... U.S. It argues that this higher bar should be set by states, by the ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
(Date:3/23/2017)... ... 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of those whose careers ... impact on the careers of all others involved. , On Monday, March 21st, ... MBI’s Hall of Fame. The induction took place during the World of Modular – ...
Breaking Medicine News(10 mins):